Symptoms are commonly attributed to other conditions and other diagnoses may have been made years before diagnosis, e.g. urinary symptoms in men attributed to common prostate conditions. Lesions may also be detected incidentally on radiological images, but can be easily misdiagnosed as malignancies.Reported cases do include some significant symptoms or findings however:

Individual organ manifestations
IgG4-RD can involve one or multiple sites in the body. With multiorgan involvement, the sites involved can be affected at the same time (synchronously) or at different unrelated periods (metachronously). Several different diseases that have been known for many years are now considered to be manifestations of IgG4-RD. These include: type 1 autoimmune pancreatitis, interstitial nephritis, Riedels thyroiditis, Mikuliczs disease, Küttners tumor, inflammatory pseudotumors (in various sites of the body), mediastinal fibrosis and some cases of retroperitoneal fibrosis. This is not a complete list, as IgG4-RD can involve any site in the body. Other affected sites, confirmed on histology to be manifestations of IgG4-RD, include:
heart; hard palate, esophagus, stomach, small intestine, rectum, adrenal gland, ovary, uterus, ureter, bladder, urachus, and synovium. Approximately 1/3 of cases exhibit increases in blood eosinophil counts, either eosinophilia or hypereosinophilia.Radiologic evidence suggestive of involvement of the superior vena cava and seminal vesicle has been reported in confirmed cases of IgG4-RD. Histology
Whatever area of the body is involved, the hallmark histopathological features of IgG4-RD are:
A dense lymphoplasmacytic (lymphocytes and plasma cells) infiltrate rich in IgG4-positive plasma cells. IgG4 immunostaining needs to be specifically requested and performed in order to detect IgG4-positive plasma cells.
For comparison, MOR full agonists are all Schedule II in the United States, whereas the mixed KOR and MOR agonists/antagonists butorphanol and pentazocine are Schedule IV in the United States. In Canada, most opioids are classified as Schedule I, but nalbuphine and butorphanol are both listed as Schedule IV substances. See also
Dinalbuphine sebacate
Samidorphan
Pain management in children


== Notes ==